Literature DB >> 11409422

Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside.

N Yuki1, M Yamada, M Koga, M Odaka, K Susuki, Y Tagawa, S Ueda, T Kasama, A Ohnishi, S Hayashi, H Takahashi, M Kamijo, K Hirata.   

Abstract

Some humans develop the axonal form of Guillain-Barré syndrome after receiving bovine brain ganglioside. On sensitization with the ganglioside mixture, all of a group of rabbits injected developed high anti-GM1 IgG antibody titers, flaccid limb weakness of acute onset, and a monophasic illness course. Pathological findings for the peripheral nerves showed predominant Wallerian-like degeneration, with neither lymphocytic infiltration nor demyelination. IgG was deposited on the axons of the anterior roots, and GM1 was proved to be present on the axons of peripheral nerves. Sensitization with purified GM1 also induced axonal neuropathy, indicating that GM1 was the immunogen in the mixture. A model of human axonal Guillain-Barré syndrome has been established that uses inoculation with a bovine brain ganglioside mixture or isolated GM1. This model may help to clarify the molecular pathogenesis of the syndrome and to develop new treatments for it.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11409422

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  62 in total

1.  Autoantobodies activate small GTPase RhoA to modulate neurite outgrowth.

Authors:  Kazim A Sheikh
Journal:  Small GTPases       Date:  2011-07-01

Review 2.  Progress in inflammatory neuropathy -the legacy of Dr Jack Griffin.

Authors:  Eva L Feldman; Richard A C Hughes; Hugh J Willison
Journal:  Nat Rev Neurol       Date:  2015-10-13       Impact factor: 42.937

3.  Anti-ganglioside antibodies alter presynaptic release and calcium influx.

Authors:  Brigitte Buchwald; Gang Zhang; Angela K Vogt-Eisele; Weiyi Zhang; Raheleh Ahangari; John W Griffin; Hanns Hatt; Klaus V Toyka; Kazim A Sheikh
Journal:  Neurobiol Dis       Date:  2007-07-14       Impact factor: 5.996

Review 4.  Diagnosis of acute neuropathies.

Authors:  Clarissa Crone; Christian Krarup
Journal:  J Neurol       Date:  2007-09-21       Impact factor: 4.849

5.  Variants of Guillain-Barré syndrome: low incidence but high impact.

Authors:  Helmar C Lehmann; Hans-Peter Hartung
Journal:  J Neurol       Date:  2009-07-25       Impact factor: 4.849

6.  Molecular mimicry: sensitization of Lewis rats with Campylobacter jejuni lipopolysaccharides induces formation of antibody toward GD3 ganglioside.

Authors:  Seigo Usuki; Stuart A Thompson; Michael H Rivner; Kyoji Taguchi; Keiko Shibata; Toshio Ariga; Robert K Yu
Journal:  J Neurosci Res       Date:  2006-02-01       Impact factor: 4.164

Review 7.  The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases.

Authors:  Alina Sesarman; Gestur Vidarsson; Cassian Sitaru
Journal:  Cell Mol Life Sci       Date:  2010-03-09       Impact factor: 9.261

Review 8.  Guillain-barré syndrome: modern theories of etiology.

Authors:  Todd A Hardy; Stefan Blum; Pamela A McCombe; Stephen W Reddel
Journal:  Curr Allergy Asthma Rep       Date:  2011-06       Impact factor: 4.806

9.  The crucial role of Campylobacter jejuni genes in anti-ganglioside antibody induction in Guillain-Barre syndrome.

Authors:  Peggy C R Godschalk; Astrid P Heikema; Michel Gilbert; Tomoko Komagamine; C Wim Ang; Jobine Glerum; Denis Brochu; Jianjun Li; Nobuhiro Yuki; Bart C Jacobs; Alex van Belkum; Hubert P Endtz
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

Review 10.  Animal models for metabolic, neuromuscular and ophthalmological rare diseases.

Authors:  Guillaume Vaquer; Frida Rivière; Maria Mavris; Fabrizia Bignami; Jordi Llinares-Garcia; Kerstin Westermark; Bruno Sepodes
Journal:  Nat Rev Drug Discov       Date:  2013-03-15       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.